Eli Lilly announced the positive results of Phase 3 clinical trial of its drug, lebrikizumab, in treating atopic dermatitis. There was a...

BMS announced that Breyanzi (lisocabtagene maraleucel) met the primary endpoint of the overall response rate in two types of...